Exagen Seeks FDA Nod on Breast Cancer Test Kit

Exagen Diagnostics Inc. is petitioning the U.S. Food and Drug Administration for approval of a DNA-based test that might enable physicians to more accurately predict incidences of breast cancer recurrence, the company revealed Thursday. The product, eXagenBC, is the first of six currently in development and can be performed and analyzed at several qualified laboratories. Based in Albuquerque, N.M., Exagen develops genomic marker-based diagnostic kits and accompanying analytical software. Additional products in the pipeline will help diagnose and predict issues related to gastroenterology, infectious diseases and general medicine. Exagen is venture backed by Tullis Dickerson & Co., vSpring Capital, and Wasatch Venture Fund.